Improving Research Standards to Restore Trust in Intranasal Oxytocin

Published:September 03, 2015DOI:
      Leng and Ludwig (
      • Leng G.
      • Ludwig M.
      Intranasal oxytocin: myths and delusions.
      ) provide the much needed first step toward an open discussion regarding the quality of intranasal oxytocin research in humans. They further highlight a clear knowledge gap in the pharmacology of intranasal drug delivery. We provide pragmatic solutions for improving research standards in this field and outline extensive evidence supporting intranasal delivery of large molecules to the brain.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Leng G.
        • Ludwig M.
        Intranasal oxytocin: myths and delusions.
        Biol Psychiatry. 2015;
      1. International Conference on Harmonisation: Good clinical practice. Consolidated guideline 1996. Available at:

      2. World Health Organization (1995): Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Annex 3 of The Use of Essential Drugs Sixth Report of the WHO Expert Committee. Geneva: Available at:

        • Rennie D.
        CONSORT revised—improving the reporting of randomized trials.
        JAMA. 2001; 273: 408-412
      3. The International Committee of Medical Journal Editors (2013): Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. Available at:

        • Freedman L.P.
        • Cockburn I.M.
        • Simcoe T.S.
        The economics of reproducibility in preclinical research.
        PloS Biol. 2015; 13: e1002165
        • Garner J.P.
        The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it?.
        Ilar J. 2014; 55: 438-456
      4. National Institutes of Health (2014): Proposed principles and guidelines for reporting preclinical research. Available at:

        • Calcagnoli F.
        • Kreutzmann J.C.
        • de Boer S.F.
        • Althaus M.
        • Koolhaas J.M.
        Acute and repeated intranasal oxytocin administration exerts anti-aggressive and pro-affiliative effects in male rats.
        Psychoneuroendocrinology. 2015; 51: 112-121
        • Watanabe T.
        • Abe O.
        • Kuwabara H.
        • Yahata N.
        • Takano Y.
        • Iwashiro N.
        • et al.
        Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial.
        JAMA Psychiatry. 2014; 71: 166-175
        • Sripada C.S.
        • Phan K.L.
        • Labuschagne I.
        • Welsh R.
        • Nathan P.J.
        • Wood A.G.
        Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex.
        Int J Neuropsychopharmacol. 2013; 16: 255-260
        • Dodhia S.
        • Hosanagar A.
        • Fitzgerald D.A.
        • Labuschagne I.
        • Wood A.G.
        • Nathan P.J.
        • et al.
        Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.
        Neuropsychopharmacology. 2014; 39: 2061-2069
        • Lochhead J.J.
        • Thorne R.G.
        Intranasal delivery of biologics to the central nervous system.
        Adv Drug Deliv Rev. 2012; 64: 614-628
        • Thorne R.G.
        • Pronk G.J.
        • Padmanabhan V.
        • Frey W.H.
        Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.
        Neuroscience. 2004; 127: 481-496
        • Dhuria S.V.
        • Hanson L.R.
        • Frey II, W.H.
        Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.
        J Pharmacol Exp Ther. 2009; 328: 312-320

      Linked Article